---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-23-000004"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2023-01-25T23:59:59+00:00"
generated_at: "2026-06-20T09:24:11.809065+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# iBio appoints Dr. Martin Brenner as Interim CEO; Felipe Duran as Interim CFO

## Summary
- Dr. Martin Brenner, previously CSO, appointed Interim CEO effective Jan. 20, 2023; receives $7,500/mo stipend plus 130,000 RSUs vesting over 12 months.
- Felipe Duran, previously VP FP&A, appointed Interim CFO effective Feb. 13, 2023; base salary increased from $300K to $350K, eligible for $140K special incentive bonus.
- Interim CEO appointment is temporary while board continues search for permanent CEO; Duran's additional retention bonus of $70K to remain through March 31, 2023.
- Both positions are at-will; severance includes 9 months base salary without cause, 12 months with change in control, plus COBRA and equity acceleration.

## SEC filing metadata
- accession: 0001420720-23-000004
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2023-01-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072023000004/0001420720-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072023000004/ibio-20230120x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-23-000004
- JSON: https://secwatch.observer/filing/0001420720-23-000004.json
- Plain text: https://secwatch.observer/filing/0001420720-23-000004.txt

## Key facts
- Executive change
  Felipe Duran was appointed as Interim Chief Financial Officer at iBio, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: and Mr. Felipe Duran, to the position of Interim Chief Financial Officer, effective as of February 13, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000142072023000004/0001420720-23-000004-index.htm
- Executive change
  Dr. Martin Brenner was appointed as Interim Chief Executive Officer at iBio, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: appointed Dr. Martin Brenner to the position of Interim Chief Executive Officer, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000142072023000004/0001420720-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.